In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Share Wars

Executive Summary

The news that William Haseltine, PhD, the chairman and CEO of Human Genome Sciences Inc. has sold 15% of his holdings in the company for some $65 million-leaving him $300 million in HGS stock-prompted us to take a look at just how well top-tier biotech CEOs have done. Dr. Haseltine's success describes a new biotech fact: for the most part, top-tier biotech CEOs are worth--at the moment--more than Big Pharma CEOs.
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel